Huntington's disease: Clinical characteristics, pathogenesis and therapies

被引:16
作者
Nakamura, Ken
Aminoff, Michael J.
机构
[1] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA
[2] Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94121 USA
关键词
D O I
10.1358/dot.2007.43.2.1050788
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Huntington's disease is a devastating disorder with no known cure. The disease results from an expanded sequence of CAG repeats in the huntingtin gene and leads to a movement disorder with associated cognitive and systemic deficits. Huntington's disease is diagnosed by genetic testing and disease progression can be followed with a variety of imaging modalities. The accumulation of aggregated huntingtin with associated striatal degeneration is evident at autopsy. The pathophysiology of Huntington's disease remains unknown, although protein aggregation, excitotoxicity, deficits in energy metabolism, transcriptional dysregulation and apoptosis may all be involved. Current pharmacologic therapy for Huntington's disease is limited and exclusively symptomatic. However, the disease is being heavily researched, and a wide range of disease-modifying therapies is currently under development. The efficacy of these therapies is being evaluated in transgenic models of Huntington's disease and in preliminary clinical trials. (c) 2007 Prous Science. All rights reserved.
引用
收藏
页码:97 / 116
页数:20
相关论文
共 183 条
[1]   Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila [J].
Agrawal, N ;
Pallos, J ;
Slepko, N ;
Apostol, BL ;
Bodai, L ;
Chang, LW ;
Chiang, AS ;
Thompson, LM ;
Marsh, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) :3777-3781
[2]   Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease [J].
Alberch, J ;
Pérez-Navarro, E ;
Canals, JM .
BRAIN RESEARCH BULLETIN, 2002, 57 (06) :817-822
[3]   A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease [J].
Almqvist, EW ;
Bloch, M ;
Brinkman, R ;
Craufurd, D ;
Hayden, MR .
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 64 (05) :1293-1304
[4]   High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia [J].
Almqvist, EW ;
Elterman, DS ;
MacLeod, PM ;
Hayden, MR .
CLINICAL GENETICS, 2001, 60 (03) :198-205
[5]   Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease [J].
Alpay, M ;
Koroshetz, WJ .
PSYCHOSOMATICS, 2006, 47 (01) :70-72
[6]  
AMINOFF MJ, 1974, LANCET, V1, P107
[7]   ACANTHOCYTOSIS AND NEUROLOGICAL DISEASE [J].
AMINOFF, MJ .
BRAIN, 1972, 95 :749-760
[8]   Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease [J].
Andreassen, OA ;
Dedeoglu, A ;
Ferrante, RJ ;
Jenkins, BG ;
Ferrante, KL ;
Thomas, M ;
Friedlich, A ;
Browne, SE ;
Schilling, G ;
Borchelt, DR ;
Hersch, SM ;
Ross, CA ;
Beal, MF .
NEUROBIOLOGY OF DISEASE, 2001, 8 (03) :479-491
[9]   Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease [J].
Andreassen, OA ;
Ferrante, RJ ;
Huang, HM ;
Dedeoglu, A ;
Park, L ;
Ferrante, KL ;
Kwon, J ;
Borchelt, DR ;
Ross, CA ;
Gibson, GE ;
Beal, MF .
ANNALS OF NEUROLOGY, 2001, 50 (01) :112-117
[10]   Striatal glucose metabolism and dopamine D-2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease [J].
Antonini, A ;
Leenders, KL ;
Spiegel, R ;
Meier, D ;
Vontobel, P ;
WeigellWeber, M ;
SanchezPernaute, R ;
deYebenez, JG ;
Boesiger, P ;
Weindl, A ;
Maguire, RP .
BRAIN, 1996, 119 :2085-2095